Swiss National Bank Sells 48,400 Shares of DexCom, Inc. (NASDAQ:DXCM)

Swiss National Bank cut its position in DexCom, Inc. (NASDAQ:DXCM) by 4.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,132,000 shares of the medical device company’s stock after selling 48,400 shares during the period. Swiss National Bank’s holdings in DexCom were worth $88,036,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DXCM. Jennison Associates LLC increased its holdings in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares during the period. Congress Asset Management Co. grew its position in DexCom by 5,456.9% during the fourth quarter. Congress Asset Management Co. now owns 1,356,941 shares of the medical device company’s stock worth $105,529,000 after buying an additional 1,332,522 shares in the last quarter. Fisher Funds Management LTD bought a new position in DexCom during the 4th quarter worth $96,507,000. Westfield Capital Management Co. LP raised its holdings in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after acquiring an additional 876,739 shares in the last quarter. Finally, Two Sigma Advisers LP lifted its position in shares of DexCom by 182.7% during the 3rd quarter. Two Sigma Advisers LP now owns 1,143,476 shares of the medical device company’s stock valued at $76,659,000 after acquiring an additional 739,000 shares during the period. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Trading Up 3.2 %

NASDAQ DXCM opened at $70.69 on Friday. The firm has a market capitalization of $27.62 billion, a PE ratio of 49.43, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The business’s 50-day moving average price is $83.99 and its two-hundred day moving average price is $76.85. The company has a current ratio of 1.47, a quick ratio of 1.28 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 12 month low of $62.34 and a 12 month high of $142.00.

DexCom (NASDAQ:DXCM) last released its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

Insider Buying and Selling

In related news, EVP Jereme M. Sylvain sold 2,090 shares of the firm’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the completion of the sale, the executive vice president now owns 83,526 shares of the company’s stock, valued at $7,259,244.66. This trade represents a 2.44 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Jacob Steven Leach sold 14,076 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at approximately $22,063,918.86. This trade represents a 4.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 104,657 shares of company stock valued at $8,019,422 over the last quarter. Insiders own 0.30% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on DXCM. Morgan Stanley raised their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Canaccord Genuity Group raised their target price on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a report on Friday, February 14th. Baird R W upgraded shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and increased their price target for the stock from $86.00 to $104.00 in a research report on Thursday, January 16th. Finally, Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday, March 4th. Four equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.